Consistent with the effect on CD8+ T-cell infiltration, the combination of ERK inhibition with anti-PD-1 antibodies led to significant tumor regression in tumors expressing HRSWT and HRSS345A, not in tumors expressing HRSS345D (Fig. 2d–f and Supplementary Fig. 4a, b). The gene discussed is MAPK1; the disease is neoplasm.